Oxford Niaspan Study: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{High density lipoprotein}} {{CMG}} ==Oxford Niaspan Study== ===Objective=== To assess the effects of high dose niacin on the progression of atherosclerosis. ===...")
 
No edit summary
Line 3: Line 3:


{{CMG}}
{{CMG}}
==Oxford Niaspan Study==
==Objective==
===Objective===
To assess the effects of high dose niacin on the progression of atherosclerosis.  
To assess the effects of high dose niacin on the progression of atherosclerosis.  


===Methods===
==Methods==
Oxford Niaspan study was a double blinded, randomized, placebo-controlled study of 2 g daily modified-release in 71 patients with HDL-C levels less than 40 mg/dL and either: 1) type 2 [[diabetes]] with coronary heart disease; or 2) carotid/peripheral atherosclerosis. All the patients were on an additional statin therapy. The change in carotid artery wall area was assessed by magnetic resonance imaging after 1 year.
Oxford Niaspan study was a double blinded, randomized, placebo-controlled study of 2 g daily modified-release in 71 patients with HDL-C levels less than 40 mg/dL and either: 1) type 2 [[diabetes]] with coronary heart disease; or 2) carotid/peripheral atherosclerosis. All the patients were on an additional statin therapy. The change in carotid artery wall area was assessed by magnetic resonance imaging after 1 year.


===Results===
==Results==
Niacin increased HDL-C by 23% and reduced low-density lipoprotein cholesterol by 19% and at 12 months niacin significantly reduced carotid wall area compared with placebo.
Niacin increased HDL-C by 23% and reduced low-density lipoprotein cholesterol by 19% and at 12 months niacin significantly reduced carotid wall area compared with placebo.


===Conclusion===
==Conclusion==
Compared with placebo, treatment with high-dose modified-release niacin along with statin therapy significantly reduced carotid atherosclerosis within 12 months.<ref name="urlEffects of high-dose modified-release nico... [J Am Coll Cardiol. 2009] - PubMed - NCBI">{{cite web |url=http://www.ncbi.nlm.nih.gov/pubmed/19874992?dopt=Abstract |title=Effects of high-dose modified-release nico... [J Am Coll Cardiol. 2009] - PubMed - NCBI |format= |work= |accessdate=}}</ref>
Compared with placebo, treatment with high-dose modified-release niacin along with statin therapy significantly reduced carotid atherosclerosis within 12 months.<ref name="urlEffects of high-dose modified-release nico... [J Am Coll Cardiol. 2009] - PubMed - NCBI">{{cite web |url=http://www.ncbi.nlm.nih.gov/pubmed/19874992?dopt=Abstract |title=Effects of high-dose modified-release nico... [J Am Coll Cardiol. 2009] - PubMed - NCBI |format= |work= |accessdate=}}</ref>


Line 22: Line 21:
[[Category:Lipopedia]]
[[Category:Lipopedia]]
[[Category:HDL]]
[[Category:HDL]]
[[Category:Clinical trials]]

Revision as of 23:24, 17 September 2013

High Density Lipoprotein Microchapters

Home

Patient information

Overview

Historical Perspective

Classification

Physiology

Pathophysiology

Causes

Low HDL
High HDL

Epidemiology and Demographics

Screening

Natural History, Complications and Prognosis

Diagnosis

HDL Laboratory Test

Treatment

Medical Therapy

Prevention

Future or Investigational Therapies

Clinical Trials

Landmark Trials

List of All Trials

Case Studies

Case #1

Oxford Niaspan Study On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Oxford Niaspan Study

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Oxford Niaspan Study

CDC on Oxford Niaspan Study

Oxford Niaspan Study in the news

Blogs on Oxford Niaspan Study

Directions to Hospitals Treating High density lipoprotein

Risk calculators and risk factors for Oxford Niaspan Study

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Objective

To assess the effects of high dose niacin on the progression of atherosclerosis.

Methods

Oxford Niaspan study was a double blinded, randomized, placebo-controlled study of 2 g daily modified-release in 71 patients with HDL-C levels less than 40 mg/dL and either: 1) type 2 diabetes with coronary heart disease; or 2) carotid/peripheral atherosclerosis. All the patients were on an additional statin therapy. The change in carotid artery wall area was assessed by magnetic resonance imaging after 1 year.

Results

Niacin increased HDL-C by 23% and reduced low-density lipoprotein cholesterol by 19% and at 12 months niacin significantly reduced carotid wall area compared with placebo.

Conclusion

Compared with placebo, treatment with high-dose modified-release niacin along with statin therapy significantly reduced carotid atherosclerosis within 12 months.[1]

References

  1. "Effects of high-dose modified-release nico... [J Am Coll Cardiol. 2009] - PubMed - NCBI".